Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference

Volition reports highly sensitive early-stage cancer detection data for its Capture-Seq liquid biopsy platform while targeting a $36 billion MCED and MRD market.

Rhea-AI Summary

VolitionRx (VNRX) presented early-stage solid cancer detection data using its Capture-Seq™ technology at the ESMO MAP conference.

In an initial cohort, the assay detected 49/49 cancers, including 23 early stage I/II cases, with no false positives among 21 healthy controls. A second blinded cohort showed detection of 13/14 later-stage cancers with 10 additional healthy controls. In a separate blinded validation cohort of 81 subjects, early-stage detection reached 95% for stage I and II colorectal and lung cancers. Volition targets a $36 billion total addressable market in early cancer detection and Minimal Residual Disease and has filed new patents to protect the Capture-Seq™ platform.

Positive

• 49/49 cancers detected with no false positives in first cohort, including 23 early stage I/II
• 13/14 later-stage cancers detected in a second blinded cohort with 10 healthy controls
• 95% detection of stage I and II colorectal and lung cancers in an 81-subject blinded validation cohort
• Targets an estimated $36 billion total addressable market in early cancer detection and MRD
• Filed a number of new patents to protect the Capture-Seq™ liquid biopsy technology

Negative

• None.

Market Context

On Aug 26, 2026, VNRX fell 11.8% after an update that included peer-reviewed Capture-Seq data. That ...

Analysis

On Aug 26, 2026, VNRX fell 11.8% after an update that included peer-reviewed Capture-Seq data. That prior market reaction diverged from the positive early-stage validation presented in this announcement.

Key Figures

First-cohort cancer detection: 49/49 cancers detected False positives: 0 Second-cohort cancer detection: 13/14 later-stage cancers detected +3 more

First-cohort cancer detection

49/49 cancers detected

Independent cohort

False positives

0

Two independent cohorts

Second-cohort cancer detection

13/14 later-stage cancers detected

Blinded validation cohort

Blinded validation cohort

81 subjects

Colorectal and lung cancer patients plus healthy controls

Early-stage detection

95% of stage I and II cancers

Blinded validation cohort

Target addressable market

$36 billion TAM

Early cancer detection and MRD

Historical Context

2 past events · Latest: Aug 26

2 events

1. Aug 26

   Capture-Seq data update

   24h Move

   -11.8%

   Company reported peer-reviewed Capture-Seq data exceeding 95% sensitivity and 95% specificity.

2. Aug 13

   2Q26 earnings report

   24h Move

   -14.8%

   Quarterly update cited the first peer-reviewed Capture-Seq liquid biopsy paper alongside operating progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

ctdna, chip-seq, mced, mrd, +1 more

5 terms

ctdna medical

"direct ChIP-seq of short CTCF-protected plasma ctDNA"

Circulating tumor DNA (ctDNA) is tiny fragments of genetic material shed by cancer cells into the bloodstream, like breadcrumbs that can reveal a tumor’s presence and genetic makeup without needing a biopsy. For investors, ctDNA matters because tests and technologies that detect and analyze these fragments can speed diagnosis, track treatment response, and signal relapse, creating commercial opportunities in diagnostics, personalized therapies, and monitoring services.

chip-seq technical

"direct ChIP-seq of short CTCF-protected plasma ctDNA"

ChIP‑seq is a laboratory method that maps where specific proteins bind to DNA across the genome by isolating those DNA fragments and reading their sequences. For investors, it matters because the results reveal regulatory “on/off” sites that guide gene activity, helping drug developers identify targets, validate mechanisms, or create diagnostic markers—like a city map showing where key workers operate during rush hour.

mced medical

"contribute to Multi-Cancer Early Detection (MCED)"

A multi-cancer early detection (MCED) test is a blood-based screening tool designed to detect signs of many different cancers from a single sample, often before symptoms appear. For investors, MCEDs matter because they represent a potential shift from disease-by-disease screening to a one-stop early-warning test, which could unlock large markets, change clinical practice, and carry regulatory, reimbursement and adoption risks similar to other breakthrough medical technologies; think of it as a smoke alarm that tries to spot many types of fires early.

mrd medical

"Minimal Residual Disease detection and treatment monitoring"

MRD stands for minimal residual disease, the tiny number of cancer cells that can remain in the body after treatment and that may not show up on routine scans. Detecting MRD is like finding a few seeds left in a garden after clearing: it helps doctors predict the chance of relapse and measure how effective a therapy is, which investors watch because MRD results can influence clinical trial success, regulatory decisions, and a drug’s market potential.

cfdna medical

"CTCF-protected plasma ctDNA from background cell free DNA"

Cell-free DNA (cfDNA) is short fragments of genetic material that float freely in the bloodstream after cells die and release their contents. Investors care because cfDNA can be sampled with a simple blood draw to reveal signs of pregnancy complications, organ damage, or cancer without invasive procedures, making it the basis for high-growth diagnostic tests, monitoring tools and companion products that can change how diseases are detected and treated.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Targets $36 Billion TAM in Early Cancer Detection and MRD.

HENDERSON, Nev., Sept. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract¹ at the European Society of Medical Oncology Molecular Analysis for Precision Oncology Conference (ESMO MAP) in London this week. The presentation entitled "Early stage I solid cancer detection by direct ChIP-seq of short CTCF-protected plasma ctDNA" and given by Dr. Andrew Retter, highlights the use of its Capture-Seq™ technology in the detection of early-stage I solid cancer.

Dr Andrew Retter, Medical Consultant, Volition, said:

"We were delighted to be selected to present in the main auditorium at this prestigious conference.

"From a clinical perspective, the proof of concept and early blinded validation results reported are extremely encouraging. In two independent cohorts we reported no false positives and detected 49/49 cancers in the first cohort (including 23 early stage I/II and 21 healthy controls) and validated it in a second blinded cohort with 13/14 later stage cancers detected with 10 additional healthy controls². 

"We also subsequently reported data from a blinded validation cohort of 81 subjects (colorectal and lung cancer patients = 59, healthy controls = 22) and the results are likewise very promising; the early-stage cancer detection of 95% of stage I and II cancers is particularly noteworthy³.

"For patients, the potential significance is huge. If validated in larger cohorts, CTCF Capture-Seq™ could contribute to Multi-Cancer Early Detection (MCED) fulfilling a significant unmet clinical need.

"We also believe that Capture-Seq™ has the potential to play a role in cancer management, including but not limited to, Minimal Residual Disease detection and treatment monitoring, either alone or potentially in combination with other technologies too."

Dr Jake Micallef, Chief Scientific Officer, Volition added:

"This new method isolated CTCF-protected plasma ctDNA from background cell free DNA bound to nucleosomes². Analysis of the isolated CTCF-protected ctDNA produced sequencing data sets for blood samples from early stage cancer patients that were absent from blood samples of healthy control subjects.

"These methodological and technological breakthroughs represent a novel liquid biopsy method for a novel class of potentially thousands of liquid biopsy sequence biomarkers. Capture-Seq™ shows potential for both a multi-cancer early detection (MCED) approach, either alone or in combination with other tests, and the detection of Minimal Residual Disease (MRD).

"We are fast-tracking the development of Capture-Seq™: conducting further studies, including competing conditions and working with oncology Key Opinion Leaders.

"Volition is, I believe, the first liquid biopsy company to focus on circulating cell free nucleoproteins and we have filed a number of new patents to protect this technology."

Details:

ESMO MAP brings together leading experts in oncology, molecular diagnostics, and precision medicine for two days of high-level exchange, collaboration, and innovation. 

10^th September, 14:55pm, Main Auditorium, London Business Design Centre

1. Conference abstract
2. Pamart, D., et al. Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy. Clin Epigenet (2026). https://doi.org/10.1186/s13148-026-02205-x
3. Data on File : Volition TAM Model

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620

Safe Harbor Statement

Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; Volition's failure to achieve healthcare system or insurance plan reimbursement for its products;  a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nu.Q^®, Nucleosomics™, Capture-PCR™, Capture-Seq™ and rNuQ™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.

View original content:https://www.prnewswire.com/news-releases/volition-presents-early-stage-i-solid-cancer-detection-at-the-esmo-map-conference-302875069.html

SOURCE VolitionRx Limited

FAQ

What is Volition's Capture-Seq™ technology and how does it work in cancer detection?

Capture-Seq™ is a liquid biopsy method that isolates CTCF-protected plasma circulating tumor DNA (ctDNA) from background cell-free DNA bound to nucleosomes. Analysis of this isolated CTCF-protected ctDNA produced sequencing data sets in blood samples from early-stage cancer patients that were absent in samples from healthy control subjects, creating a novel class of potentially thousands of liquid biopsy sequence biomarkers.

What clinical applications does Volition envisage for Capture-Seq™?

The company states that CTCF Capture-Seq™ could contribute to Multi-Cancer Early Detection (MCED) and may play a role in cancer management, including Minimal Residual Disease (MRD) detection and treatment monitoring, either alone or in combination with other technologies.

How is Volition advancing the development of Capture-Seq™?

Volition indicates it is fast-tracking development of Capture-Seq™ by conducting further studies, including work on competing conditions, and collaborating with oncology Key Opinion Leaders.

When and where is Volition presenting its Capture-Seq™ data at ESMO MAP?

The presentation is scheduled for 10th September at 14:55 in the Main Auditorium at the London Business Design Centre during the ESMO Molecular Analysis for Precision Oncology (MAP) conference.